Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibVascular Complications of Cancer ChemotherapyWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentRisk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisGuidance for the prevention and treatment of cancer-associated venous thromboembolismIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsZebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plantsRisk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsPonatinib reduces viability, migration, and functionality of human endothelial cells.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Cancer and Venous Thromboembolic Disease: A Review.Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsElucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer.Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisClinical guide SEOM on venous thromboembolism in cancer patients.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancerAn update on cardio-oncology.Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisPhysiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryRisks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisCardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesCardiotoxicity of molecularly targeted agentsIncreased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysisNovel agents in renal carcinoma: a reality check.Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinomaManagement of antiangiogenic therapy-induced hypertension.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyMetastasectomy after targeted therapy in patients with advanced renal cell carcinoma.Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.Cancer and coagulation.A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentIncidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
P2860
Q21261282-235CE555-28DF-43E8-BFAF-09C08F68C730Q26766269-16F1CFDE-E513-4812-9ED1-E274BB63A4EBQ26782585-BA5C992C-79FF-4267-B676-7081990FD28AQ26822790-801E4262-881B-47B4-9E3A-4083F00CCE0AQ26991991-E92972D3-D932-4606-8158-BD38560EB751Q27013665-BD722DF3-A504-403C-9673-DC6EB2F99A3EQ27026453-31851EF5-06A1-4B32-8AA2-5324D995064BQ28069131-9110E112-6C4E-4D58-BFC9-A82426D22891Q28079328-ECE059FD-65B7-4C93-B49D-2967B316B1B1Q28477190-20FCA26C-F7DC-4386-98C7-7FA60E7AB0FBQ28551983-FB4EFF0F-BB47-4BB2-885E-D7DF049E0AD4Q33364077-9C60D36C-D466-4DFD-9B2F-1E709EF89895Q33398485-73E62E42-A9C6-4099-AA1C-FD41E8FB422AQ33408049-83EFDF7A-0560-4450-A6DB-0F6E11D0FB74Q33439089-376ED370-95CC-43E4-AACD-559B2CB3BD92Q34097937-E20A3643-AECD-440A-82B5-59687515FC45Q34293090-1B232A03-9F99-4CB7-93D5-4C35D0323427Q34352627-60645914-ED32-4479-AAC0-FCD617D16DC2Q34445829-12C967CE-AD0C-44E9-A442-B1B43968AD81Q34487244-3E8F8E8D-6E5C-45B4-87BC-9BE8C8369B1CQ34537664-D9BFE06A-1AAB-4150-8A66-941B6DE68765Q34553530-B05D5A85-464F-4C1F-8ABC-9C3E6FDA8096Q34554398-85DA5A7C-CB66-453E-966E-C9FE13BF853FQ34637564-E554358C-8C4B-4F54-872D-7698613F16C9Q34650059-0DC1161E-62C0-401B-815D-29D5B253F6CDQ34778631-35CA3ABF-6780-4954-B73E-0C1E675F16DEQ35039202-3085E200-8DB8-49B4-89E3-72005347899BQ35118673-98FBC5C5-2A31-45B5-A538-BB881A61C302Q35584182-43C93D6F-7EEE-48BA-991E-111CE0EDB523Q35878459-BA7A407C-121A-4E4E-BE10-1DFC5A849D61Q36024704-0E3982F4-D978-471B-B2E7-721399F3E90BQ36061173-1D49A7C4-337A-4C44-A9ED-4C6084416D73Q36150570-C5D2E97A-F49C-47C8-857B-8014F55665D2Q36170252-7F7CFABE-0E35-4D7E-A725-B068A37737B9Q36318627-06EE0169-A2F3-4C6A-B83B-F9E0865395D2Q36344279-42D1DD05-32BC-464D-B52D-CCDAC8ADD661Q36351120-F322A13C-E1DD-4FCE-8670-6C76B067D77AQ36391554-98A0591F-A871-4B8F-9CAF-BDFE94A28509Q36716739-EFB21B43-3174-4F29-A995-C6B3A250796AQ36729895-AD4EF584-3D5F-4916-BE50-AE7B96D40F5A
P2860
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@en
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@nl
type
label
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@en
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@nl
prefLabel
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@en
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@nl
P2093
P356
P1476
Risk of arterial thromboemboli ...... a-analysis of clinical trials.
@en
P2093
Fabio A B Schutz
Joaquim Bellmunt
Jonathan E Rosenberg
Toni K Choueiri
P304
P356
10.1200/JCO.2009.27.2757
P407
P50
P577
2010-03-29T00:00:00Z